title: A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
authors.affiliation: Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University katherine.borden@umontreal.ca sarit.assouline@mcgill.ca.
authors.forename: Sarit
authors.initials: S
authors.lastname: Assouline
authors.affiliation: Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal.
authors.forename: Biljana
authors.initials: B
authors.lastname: Culjkovic-Kraljacic
authors.affiliation: Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
authors.forename: Julie
authors.initials: J
authors.lastname: Bergeron
authors.affiliation: Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University.
authors.forename: Stephen
authors.initials: S
authors.lastname: Caplan
authors.affiliation: Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University.
authors.forename: Eftihia
authors.initials: E
authors.lastname: Cocolakis
authors.affiliation: Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University.
authors.forename: Caroline
authors.initials: C
authors.lastname: Lambert
authors.affiliation: Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University.
authors.forename: Cara J
authors.initials: CJ
authors.lastname: Lau
authors.affiliation: Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal.
authors.forename: Hiba Ahmad
authors.initials: HA
authors.lastname: Zahreddine
authors.affiliation: Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University.
authors.forename: Wilson H
authors.initials: WH
authors.lastname: Miller
authors.affiliation: Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal katherine.borden@umontreal.ca sarit.assouline@mcgill.ca.
authors.forename: Katherine L B
authors.initials: KL
authors.lastname: Borden
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D003561:Cytarabine / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D039561:Eukaryotic Initiation Factor-4E / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012254:Ribavirin / Q000008:administration & dosage; D016879:Salvage Therapy; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D039561:Eukaryotic Initiation Factor-4E; D003561:Cytarabine; D012254:Ribavirin
keywords: AML; drug resistance; eIF4E; phase I; ribavirin